CYP2C9 VE VKORC1 GENLERİNİN PROSTAT KANSERİ ETİYOLOJİSİNDEKİ ROLLERİNİN ARAŞTIRILMASI

Amaç: Çalışmamızda, Sitokrom p450 enzimlerini kodlayan CYP ve vitamin K epoksit redüktaz komplekssubünit 1 enzimini kodlayan VKORC1 genlerinin altgruplarındaki tek nükleotit polimorfizmlerinin bireyselve ortak etkilerinin prostat kanseri hastalarında araştırılması amaçlanmıştır.Gereç ve Yöntem: Çalışmamıza 48 prostat kanseri tanılı erkek hasta ve 48 sağlıklı erkek birey dâhil edildi.Hasta grubu prostat tanısı almış yaş aralığı 49-86 olangönüllü bireylerden, kontrol grubu ise prostat kanseriolmadığı belirlenmiş, 51-86 yaş grubundaki gönüllübireylerden seçilmiştir. Katılımcıların genomik DNA’larının PCR ürünleri mikroarray yöntemi ile ayrıntılı olarak genotiplenmiştir.Bulgular: CYP2C9 ve VKORC1 enzimlerini kodlayangenlerin alt gruplarının polimorfizm karşılaştırmalarıhasta ve kontrol grubu arasında yüzde olarak önemlifarklar göstermiştir. Örneğin VKORC1 6853 G>Cpolimorfizmi için kontrol grubunda CC alleli %25 ikenhasta grubunda %34,5 olarak tespit edildi. AyrıcaCYP2C9 *3 A>C değişimi için kontrol grubunda CC alleli%79,16 iken hasta grubunda %87,5 olarak tespit edilmiştir.Sonuç: Çalışmamızda yüzde olarak hasta ve kontrolgrubunda önemli farklar görülmüştür. CYP2C9 veVKORC1 geninin alt gruplarının analizleri sonucundaistatistiksel anlamlılık tespit edilmemiştir. Bunun sebebinin örnek sayısı azlığı ile alakalı olduğu ve ileri çalışmaların konuyu aydınlatacağı düşünülmüştür.

THE ROLE OF CYP2C9 AND VKORC1 GENES IN THE ETHİOLOGY OF PROSTATE CANCER

Objective: Our aim was to investigate possible effects of the genes encoding cytochrome p450 (CYP) and vitamine K epoxide reductase complex subunit 1 (VKORC1) in prostate cancer patients. Methods: 48 prostate cancer diagnosed and 48 healty males were included in our study. The volunteers’ age range with prostate cancer was 49-86, while the control group’s was 51-86 years. Genomic DNA was amplified with PCR, targeted regions were genotyped using microarray. Result: The percentages between patient and control groups showed significant differences when the genes encoding CYP2C9 and VKORC1 enzymes were compared. For example, the CC allele of VKORC1 6853 G> C polymorphism found to be %25 in the control and %34.5 in the patient group. In addition CC allele of CYP2C9* 3 A> C change found %79.16 in the control and %87.5 in the patient group. Conclusion: Significant differences were seen in number and percentage of patients and control groups in our study. As a result of analysis of the subgroups of CYP2C9 gene and of the VKORC1 gene, statistical significance was not observed, nevertheless, we expect statistical significiance when the numbers of individual is increased.

PDF

___

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. EurJCancer. 2001; 37: 4–66.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002; 55: 74-108.
3. Coffey DS. Similarities Of Prostate And Breast Cancer: Evolution, Diet, And Estrogens. Urology. 2001; 57: 31-38.
4. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
5. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification Of Clinical Presentation Of Prostate Tumors By A Novel Genetic Variant In Cyp3a4. J Natl Cancer Inst. 1998; 90: 1225-1229.
6. Kumagai J, Fujimura T, Takahashi S, Urano T, Ogushi T, Horie-Inoue K et al. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate. 2007; 1;67: 1029–1037.
7. Yin I, Miyata T. 'Warfarin dose and the of CYP2C9 and VKORC I Jarionnle and perspectives. Thfombosls Research. 2007.
8. Vermeer C, Knapen MHJ, Schurgers LJ. Vitamin K and metabolic bone disease. Clin Pathol. 1998; 51: 424-426.
9. Holzer G, Grasse AV, Zehetmayer S, Bencur P, Bieglmayer C, Mannhalter C. Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study. Transl Res. 2010; 156 (1): 37-44.
10. Wang Y, Zhen Y, Shi Y, Chen J, Zhang C, Wang X et al. Vitamin K epoxide reductase: a protein involved in angiogenesis. Mol Cancer Res. 2005; 3:317–323.
11. New AS. Bone health: the role of micronutrients. Br Med Bull. 1999; 55(3):619-633.
12. Monographs. Vitamin K2. Altern Med Rev. 2009; 14 (3): 284-293.
13. Montes R, Gaona ER, Martinez-Gonzalez MA, Alberca I, Hermid J. The 1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. British Journal of Haematology. 2006; 133: 183–187.
14. Walsh PC, Retik BA, Vaughan ED, Wein AJ. Campbell’s urology. 9th ed. Philadelphia, Saunders Co. 2007; 3001-3221.
15. Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G, Ozawa S. CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectalcancers. Int J Oncol. 2009; 34(4): 1085- 1091.
16. Liao LH, Zhang H, Lai MP, Lau KW, Lai AK, Zhang JH et al. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. Clin Chim Acta. 2007; 380(16): 191-196.
17. Levkovich NN, Gorovenko NG, Myasoedov DV. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. Exp Oncol. 2011; 33(3): 136–139
18. Gan CQ, Wang XY, Cao YD, Ye WX, Liu H, Sun YY. Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res. 2011; 10(4):3514-3519.
19. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Mechanisms of disease, the pathogenesis of coronary artery disease and the acute coronary syndromes (part one). N Engl J Med. 1992; 326(1): p.242–250
20. Nimptsch K, Rohrmann S, Nieters A, Linseisen J. Serum Undercarboxylated Osteocalcin as Biomarker of Vitamin K Intake and Risk of Prostate Cancer: A Nested Case- Control Study in the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2009; 18(1): 49-56
21. Kellerman G, Shaw CR, Luyten-Kellerman M. Aryl Hydrocarbon Hydroxylase İnducibility And Bronchogenic Carcinoma. N. Engl. J. Med. 1973;298: 934-937.
22. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet. 2011; 26: 516-522. 23. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR.
Metabolic Oxidation Phenotypes As Markers For Susceptibility To Lung Cancer. Nature, 1984; 312: 169-170.
24. Wang Y, Luo F, Zheng Y, Fan X, Chen J, Zhang Y, Hui R. VKORC1 haplotypes influence the performance characteristics of PIVKAII for screening of hepatocellular carcinoma. Clin Chem Lab Med. 2010; 48: 1475-9.
25. Wijen PA, Bekers O, Drent M. Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carries. MolDiagn Ther. 2011; 15: 177-80
26. Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev. 2003; 8: 303-318.